Literature DB >> 28008685

Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy.

Daniele Lilleri1, Giuseppe Gerna1.   

Abstract

Immune control of primary human cytomegalovirus (HCMV) infection appears to depend on the interaction of humoral and T-cell responses. In this review, we have separately explored the 2 arms of the immune response to primary HCMV infection in HCMV-seronegative pregnant women transmitting (T) or not transmitting (NT) the infection to the fetus, with the objective of correlating the immune risk factors associated with vertical HCMV transmission. As for the humoral response, the following findings were documented: (i) in competitive binding assays, antibody titers to different antigenic sites of the gH pentamer complex were significantly lower in T compared with NT women; (ii) in addition, the number of neutralization sites recognized by T was significantly lower compared with NT women; (iii) the plaque formation inhibition assay showed a faster kinetics and a higher titer in NT women. As for T-cell immunity, the delayed expression of 3 immunological parameters (lymphoproliferative response, CD45RA reexpression in both CD4+ and CD8+ HCMV-specific T cells, and interleukin-2 production by HCMV-specific CD4+ T cells) were significantly associated with vertical transmission. This overview provides important information at the population level, which may help to inform the evaluation of interventions such as vaccination or treatments designed to interrupt intrauterine transmission of HCMV during primary infection. However, although we are waiting for an HCMV vaccination to become available, we emphasize that none of these parameters can be prognostically used on an individual basis because of the great variation in values among women.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  congenital infection; human cytomegalovirus; immune protection; pregnancy; primary infection

Mesh:

Substances:

Year:  2016        PMID: 28008685     DOI: 10.1002/rmv.1921

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  23 in total

1.  Preventing Infection by Human Cytomegalovirus.

Authors:  Stanley A Plotkin
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

2.  Choice of Study Populations for Vaccines.

Authors:  Paul Griffiths; Brenna Hughes
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

3.  Clinical Diagnostic Testing for Human Cytomegalovirus Infections.

Authors:  Raymund R Razonable; Naoki Inoue; Swetha G Pinninti; Suresh B Boppana; Tiziana Lazzarotto; Liliana Gabrielli; Giuliana Simonazzi; Philip E Pellett; D Scott Schmid
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 4.  Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.

Authors:  Astrid Krmpotić; Jürgen Podlech; Matthias J Reddehase; William J Britt; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2019-03-28       Impact factor: 3.402

5.  Inclusion of the Viral Pentamer Complex in a Vaccine Design Greatly Improves Protection against Congenital Cytomegalovirus in the Guinea Pig Model.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

Review 6.  Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Authors:  Mark R Schleiss; Sallie R Permar; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

7.  Requirements for guinea pig cytomegalovirus tropism and antibody neutralization on placental amniotic sac cells.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2020-02-18       Impact factor: 3.891

Review 8.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

Review 9.  Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections.

Authors:  Sallie R Permar; Mark R Schleiss; Stanley A Plotkin
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 10.  CMV-Specific Cell-Mediated Immunity in Immunocompetent Adults with Primary CMV Infection: A Case Series and Review of the Literature.

Authors:  Angela Chiereghin; Gabriella Verucchi; Tiziana Lazzarotto
Journal:  Viruses       Date:  2021-05-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.